
|Videos|May 16, 2022
Dr. Stephen Savage discusses molecular testing and unmet needs in prostate cancer
Author(s)Urology Times staff
“We really try to be careful about testing, especially when it's a potential burden of costs on the patient. What we really look at is where it's going to have an impact,” says Stephen J. Savage, MD.
Advertisement
In this interview, Stephen J. Savage, MD, discusses current research he’s working on, the role of molecular testing in prostate cancer as well as unmet needs in treating the disease. Savage is director of minimally invasive urology at the Medical University of South Carolina, Charleston.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












